Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al

Arthritis Rheum. 2009 Sep 15;61(9):1281-2. doi: 10.1002/art.24726.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Contraindications
  • Humans
  • Lupus Erythematosus, Systemic / drug therapy*
  • Lupus Erythematosus, Systemic / pathology
  • Lymphocyte Depletion
  • Randomized Controlled Trials as Topic
  • Rituximab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Rituximab